These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 26685676)

  • 1. Shiga toxins: from structure and mechanism to applications.
    Chan YS; Ng TB
    Appl Microbiol Biotechnol; 2016 Feb; 100(4):1597-1610. PubMed ID: 26685676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection against Shiga Toxins.
    Kavaliauskiene S; Dyve Lingelem AB; Skotland T; Sandvig K
    Toxins (Basel); 2017 Feb; 9(2):. PubMed ID: 28165371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vero toxins (Shiga-like toxins) produced by enterohemorrhagic Escherichia coli (verocytotoxin-producing E. coli).
    Takeda Y; Kurazono H; Yamasaki S
    Microbiol Immunol; 1993; 37(8):591-9. PubMed ID: 8246822
    [No Abstract]   [Full Text] [Related]  

  • 4. Shiga toxin-glycosphingolipid interaction: Status quo of research with focus on primary human brain and kidney endothelial cells.
    Legros N; Pohlentz G; Steil D; Müthing J
    Int J Med Microbiol; 2018 Dec; 308(8):1073-1084. PubMed ID: 30224239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shiga Toxins: An Update on Host Factors and Biomedical Applications.
    Liu Y; Tian S; Thaker H; Dong M
    Toxins (Basel); 2021 Mar; 13(3):. PubMed ID: 33803852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shiga toxins, glycosphingolipid diversity, and endothelial cell injury.
    Müthing J; Schweppe CH; Karch H; Friedrich AW
    Thromb Haemost; 2009 Feb; 101(2):252-64. PubMed ID: 19190807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelial heterogeneity in Shiga toxin receptors and responses.
    Obrig TG; Louise CB; Lingwood CA; Boyd B; Barley-Maloney L; Daniel TO
    J Biol Chem; 1993 Jul; 268(21):15484-8. PubMed ID: 8340376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocytosis and retrograde transport of Shiga toxin.
    Sandvig K; Bergan J; Dyve AB; Skotland T; Torgersen ML
    Toxicon; 2010 Dec; 56(7):1181-5. PubMed ID: 19951719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Uses of Bacterial Subunit Toxins.
    Lingwood C
    Toxins (Basel); 2021 May; 13(6):. PubMed ID: 34073185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receptor affinity, stability and binding mode of Shiga toxins are determinants of toxicity.
    Shimizu T; Sato T; Kawakami S; Ohta T; Noda M; Hamabata T
    Microb Pathog; 2007; 43(2-3):88-95. PubMed ID: 17532600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shiga toxin binds human platelets via globotriaosylceramide (Pk antigen) and a novel platelet glycosphingolipid.
    Cooling LL; Walker KE; Gille T; Koerner TA
    Infect Immun; 1998 Sep; 66(9):4355-66. PubMed ID: 9712788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Change in conformation with reduction of alpha-helix content causes loss of neutrophil binding activity in fully cytotoxic Shiga toxin 1.
    Brigotti M; Carnicelli D; Arfilli V; Rocchi L; Ricci F; Pagliaro P; Tazzari PL; Vara AG; Amelia M; Manoli F; Monti S
    J Biol Chem; 2011 Oct; 286(40):34514-21. PubMed ID: 21832076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shiga Toxins as Multi-Functional Proteins: Induction of Host Cellular Stress Responses, Role in Pathogenesis and Therapeutic Applications.
    Lee MS; Koo S; Jeong DG; Tesh VL
    Toxins (Basel); 2016 Mar; 8(3):. PubMed ID: 26999205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ether lipid precursor hexadecylglycerol protects against Shiga toxins.
    Bergan J; Skotland T; Lingelem AB; Simm R; Spilsberg B; Lindbäck T; Sylvänne T; Simolin H; Ekroos K; Sandvig K
    Cell Mol Life Sci; 2014 Nov; 71(21):4285-300. PubMed ID: 24740796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shiga Toxins as Antitumor Tools.
    Robert A; Wiels J
    Toxins (Basel); 2021 Sep; 13(10):. PubMed ID: 34678982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trafficking of Shiga toxin/Shiga-like toxin-1 in human glomerular microvascular endothelial cells and human mesangial cells.
    Warnier M; Römer W; Geelen J; Lesieur J; Amessou M; van den Heuvel L; Monnens L; Johannes L
    Kidney Int; 2006 Dec; 70(12):2085-91. PubMed ID: 17063173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shiga toxin-associated hemolytic uremic syndrome: effect of sodium butyrate on sensitivity of human umbilical vein endothelial cells to Shiga toxin.
    Louise CB; Kaye SA; Boyd B; Lingwood CA; Obrig TG
    Infect Immun; 1995 Jul; 63(7):2766-9. PubMed ID: 7790096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The induction of apoptosis by Shiga toxins and ricin.
    Tesh VL
    Curr Top Microbiol Immunol; 2012; 357():137-78. PubMed ID: 22130961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infection by Shiga toxin-producing Escherichia coli: an overview.
    Karmali MA
    Mol Biotechnol; 2004 Feb; 26(2):117-22. PubMed ID: 14764937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shiga toxin and its use in targeted cancer therapy and imaging.
    Engedal N; Skotland T; Torgersen ML; Sandvig K
    Microb Biotechnol; 2011 Jan; 4(1):32-46. PubMed ID: 21255370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.